Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors.
about
Plasma serotonin levels and the platelet serotonin transporterThe Trafficking of the Water Channel Aquaporin-2 in Renal Principal Cells-a Potential Target for Pharmacological Intervention in Cardiovascular DiseasesPharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptorsPharmacological chaperoning: a primer on mechanism and pharmacologyLuteinizing hormone receptor ectodomain splice variant misroutes the full-length receptor into a subcompartment of the endoplasmic reticulum.The pseudo signal peptide of the corticotropin-releasing factor receptor type 2a decreases receptor expression and prevents Gi-mediated inhibition of adenylyl cyclase activityInefficient maturation of the rat luteinizing hormone receptor. A putative way to regulate receptor numbers at the cell surfaceHow genetic errors in GPCRs affect their function: Possible therapeutic strategiesA conserved motif in the membrane proximal C-terminal tail of human muscarinic m1 acetylcholine receptors affects plasma membrane expression.Altered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus.Minireview: the intimate link between calcium sensing receptor trafficking and signaling: implications for disorders of calcium homeostasis.Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs.The N terminus of monoamine transporters is a lever required for the action of amphetaminesCalcium-sensing receptor biosynthesis includes a cotranslational conformational checkpoint and endoplasmic reticulum retentionChaperoning G protein-coupled receptors: from cell biology to therapeuticsGABA acts as a ligand chaperone in the early secretory pathway to promote cell surface expression of GABAA receptorsAdenosine A2A receptor is involved in cell surface expression of A2B receptor.Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptorNovel mutation in the AVPR2 gene in a Danish male with nephrogenic diabetes insipidus caused by ER retention and subsequent lysosomal degradation of the mutant receptor.Helix 8 and the i3 loop of the muscarinic M3 receptor are crucial sites for its regulation by the Gβ5-RGS7 complex.Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptorsNeuronal gamma-aminobutyric acid (GABA) type A receptors undergo cognate ligand chaperoning in the endoplasmic reticulum by endogenous GABA.Regulation of G protein-coupled receptor export trafficking.Chaperoning of the A1-adenosine receptor by endogenous adenosine - an extension of the retaliatory metabolite concept.Differences in Signal Activation by LH and hCG are Mediated by the LH/CG Receptor's Extracellular Hinge RegionImpact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targetsRefolding of misfolded mutant GPCR: post-translational pharmacoperone action in vitro.Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment.Chemical and pharmacological chaperones as new therapeutic agents.Inside job: ligand-receptor pharmacology beneath the plasma membrane.Increased plasma membrane expression of human follicle-stimulating hormone receptor by a small molecule thienopyr(im)idine.Recruitment of a cytoplasmic chaperone relay by the A2A adenosine receptor.Pharmacochaperone-mediated rescue of calcium-sensing receptor loss-of-function mutants.Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.Enhancement of the surface expression of G protein-coupled receptors.Chaperone-like effects of cell-permeant ligands on opioid receptors.Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development.Behind the curtain: cellular mechanisms for allosteric modulation of calcium-sensing receptors.Congenital nephrogenic diabetes insipidus: the current state of affairs.The integrity of the glycine co-agonist binding site of N-methyl-D-aspartate receptors is a functional quality control checkpoint for cell surface delivery.
P2860
Q24306106-8EACC0FC-7832-447F-9469-418F38084654Q26768170-89120301-1246-41C1-990E-4A52806CC005Q26992276-AACEDB6E-217B-46E4-B8BA-D2B1F8E98358Q27001695-821497A5-9FA1-40BB-9CDA-75723EF4E0F9Q28573360-49EA54E0-4934-4EE9-B52F-BF0873C41478Q28577197-850208A6-A4A5-4246-A0AA-178E6538D782Q28577566-047FDA5C-B00F-40B6-82F0-F333B3BE1A75Q28646207-DF54DAED-5940-49B4-A48C-D6FA13731F0DQ33574929-3E2533EF-7765-4A21-9B41-1DCBE21E3BE8Q33632079-BF3993E0-ACBE-42FE-81E6-DE0968AD3272Q33636300-8BE40A90-9980-4D3F-BAB1-58685FEB04E6Q33699210-D0D32F07-28A4-4452-9239-5128E6A84A5BQ33796294-BD1C24EB-840B-4767-9A75-3FC04B02F39DQ33924278-2CF87BF7-1EAA-4CA2-8B4B-1D5026B43F3CQ33927508-0F863E3E-B73C-4724-857B-23AFC7627549Q34140020-76894A72-1523-4D4E-9F8B-F72A21EEF65CQ34385959-BDFB1709-03AC-47FB-9BB0-E3FC2BE291B3Q34770179-29B422BB-FD8C-446F-9A82-74ACE32C14BDQ35012380-EAC84BC7-4E62-442D-919C-F646D3243ADFQ35053995-69AFDA07-026D-4A1C-9267-A9B881CF53B0Q35606973-D22607AE-56C2-4723-BA40-9C36C5A21A87Q35617513-EB6B216F-B85A-4894-8034-BA7C26880DEEQ35827970-1FC28757-36CF-46BB-A556-B442C59A6E7DQ35885389-4362F2EB-928E-414E-97B7-E2A1937E1AE6Q36098101-FDB2AB6B-2246-4BEB-A5FF-49573260F55CQ36316001-51B2FEBE-C77A-4C7F-9E24-72A71E208EDAQ36316416-0387A92D-A871-4FC6-A6BC-3017AEF3C9C8Q36724058-CBDAD465-612A-4E99-B0EC-8802959B41A2Q36863386-377C4C5B-736A-466F-B059-D1899062E6FDQ36989788-8DEA1421-F8D8-4A8C-B614-0612982F8E09Q37071467-A6E35F22-9823-4584-BFF6-D197A9081D69Q37213835-6E56E61B-838D-45E4-9604-9B9B13602B18Q37244874-0D0B3F31-58E7-48FC-ADEE-7157AEB78181Q37274407-0A711A23-AE41-4349-809C-7823287E6A13Q37316198-FC04298B-AB2D-4CBC-BDAD-B1DDD8712032Q37410011-3659D9BC-4424-439B-A4B4-DC3C80FF2BBBQ37627169-5B4806EF-0BCA-4DF0-8C68-16B7E76FA08BQ37862353-D04F94EA-3949-4154-89BC-6858E19BA5FFQ37994652-F8E90F75-2BFB-4E76-81AF-AEBACE6DC23BQ39920228-BA629F6A-AA70-427B-BA39-8F800DCADCB4
P2860
Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors.
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Pharmacochaperones post-transl ...... tant vasopressin V2 receptors.
@ast
Pharmacochaperones post-transl ...... tant vasopressin V2 receptors.
@en
type
label
Pharmacochaperones post-transl ...... tant vasopressin V2 receptors.
@ast
Pharmacochaperones post-transl ...... tant vasopressin V2 receptors.
@en
prefLabel
Pharmacochaperones post-transl ...... tant vasopressin V2 receptors.
@ast
Pharmacochaperones post-transl ...... tant vasopressin V2 receptors.
@en
P2093
P356
P1476
Pharmacochaperones post-transl ...... tant vasopressin V2 receptors.
@en
P2093
Alexander Oksche
Anja Löffler
Burkhard Wiesner
Gerd Krause
Jens Furkert
Michael Schaefer
Ralf Schülein
Ricardo Hermosilla
Stefan Wüller
Walter Rosenthal
P304
47254-47263
P356
10.1074/JBC.M408154200
P407
P577
2004-08-19T00:00:00Z